Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma

PLoS ONE

Volumn 12, Issue 4, 2017, Pages

  Brencicova, Eva ^a,e   Jagger, Ann L ^a   Evans, Hayley G ^a,b   Georgouli, Mirella ^a   Laios, Alex ^c   Montalto, Steve Attard ^d   Mehra, Gautam ^d   Spencer, Jo ^a   Ahmed, Ahmed A ^c   Raju Kankipati, Shanti ^d   Taams, Leonie S ^a,b   Diebold, Sandra S ^a,f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BERN   (Switzerland)

^f NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; POLYINOSINIC POLYCYTIDYLIC ACID; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROSTAGLANDIN E2; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR; VASCULOTROPIN A; IMIDAZOLE DERIVATIVE; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; ASCITES; BENIGN NEOPLASM; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL VIABILITY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROADENOMA; FLOW CYTOMETRY; HUMAN; IMMUNE DEFICIENCY; MIXED LYMPHOCYTE REACTION; MONOCYTE; MULTICENTER STUDY; OVARY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; AGONISTS; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; OVARY TUMOR; PATHOLOGY; T LYMPHOCYTE;

ANTIBODIES, NEUTRALIZING; ANTIGENS, CD86; ASCITES; CELLS, CULTURED; DENDRITIC CELLS; DINOPROSTONE; FEMALE; HUMANS; IMIDAZOLES; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MONOCYTES; OVARIAN NEOPLASMS; POLY I-C; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 85017408613     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0175712     Document Type: Article

References (47)

1. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nature reviews Clinical oncology. 2013. Epub 2013/02/06.
2. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol. 2010; 3:7. Epub 2010/02/12. https://doi.org/10.1186/ 1756-8722-3-7 PMID: 20146807
3. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature medicine. 2004; 10(9):942-9. Epub 2004/08/24. https://doi.org/10.1038/nm1093 PMID: 15322536
4. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. The Journal of experimental medicine. 2006; 203(4):871-81. Epub 2006/04/12. https://doi.org/10.1084/jem.20050930 PMID: 16606666
5. Giuntoli RL 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer research. 2009; 29(8):2875-84. Epub 2009/08/08. PMID: 19661290
6. Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecologic oncology. 2010; 117(2):366-72. Epub 2010/02/11. https://doi.org/10.1016/j.ygyno.2010.01.019 PMID: 20144842
7. Mustea A, Konsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer research. 2006; 26(2C):1715-8. Epub 2006/04/19. PMID: 16617566
8. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro endocrinology letters. 2010; 31(3):375-83. Epub 2010/07/01. PMID: 20588232
9. Chen LL, Ye F, Lu WG, Yu Y, Chen HZ, Xie X. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J Obstet Gynaecol Res. 2009; 35(2):212-8. Epub 2009/04/02. https://doi. org/10.1111/j.1447-0756.2008.00935.x PMID: 19335794
10. Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol. 1999; 20(3):177-81. Epub 1999/07/20. PMID: 10410879
11. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer research. 2007; 67(2):585-92. Epub 2007/01/20. https://doi.org/10.1158/0008-5472. CAN-06-2941 PMID: 17234767
12. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer research. 2012; 72 (1):66-75. Epub 2011/11/09. https://doi.org/10.1158/0008-5472.CAN-11-2178 PMID: 22065722
13. Johnson TS, Munn DH. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunological investigations. 2012; 41(6-7):765-97. Epub 2012/09/29. https://doi.org/10. 3109/08820139.2012.689405 PMID: 23017145
14. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England journal of medicine. 2003; 348(3):203-13. Epub 2003/01/17. https://doi.org/10.1056/NEJMoa020177 PMID: 12529460
15. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102 (51):18538-43. Epub 2005/12/14. https://doi.org/10.1073/pnas.0509182102 PMID: 16344461
16. Wertel I, Polak G, Bednarek W, Barczynski B, Rolinski J, Kotarski J. Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry Part B, Clinical cytometry. 2008; 74(4):251-8. Epub 2008/02/28. https://doi.org/10.1002/cyto.b.20410 PMID: 18302193
17. Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT, et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer research. 2009; 69(18):7329-37. Epub 2009/09/10. https://doi.org/10.1158/0008-5472.CAN-09-0835 PMID: 19738057
18. Joffre O, Nolte MA, Sporri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev. 2009; 227(1):234-47. Epub 2009/01/06. https://doi.org/ 10.1111/j.1600-065X.2008.00718.x PMID: 19120488
19. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010; 28:367-88. Epub 2010/03/03. https://doi.org/10.1146/annurev.immunol. 021908.132603 PMID: 20192808
20. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012; 12(8):557-69. Epub 2012/07/14. https://doi.org/10.1038/nri3254 PMID: 22790179
21. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. European journal of immunology. 2001; 31(11):3388-93. Epub 2001/12/18. PMID: 11745357
22. Boonstra A, Rajsbaum R, Holman M, Marques R, Asselin-Paturel C, Pereira JP, et al. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88-and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol. 2006; 177(11):7551-8. Epub 2006/11/23. PMID: 17114424
23. Brencicova E, Diebold SS. Antibody-mediated depletion of immunosuppressive factors from ovarian carcinoma-associated ascites for investigation of paracrine versus autocrine effects. J Immunol Methods. 2017; 443:18-25. Epub 2017/02/06. https://doi.org/10.1016/j.jim.2017.01.008 PMID: 28159551
24. Legler DF, Krause P, Scandella E, Singer E, Groettrup M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol. 2006; 176 (2):966-73. Epub 2006/01/06. PMID: 16393982
25. Poloso NJ, Urquhart P, Nicolaou A, Wang J, Woodward DF. PGE(2) differentially regulates monocytederived dendritic cell cytokine responses depending on receptor usage (EP(2)/EP(4)). Mol Immunol. 2013; 54(3-4):284-95. Epub 2013/01/23. https://doi.org/10.1016/j.molimm.2012.12.010 PMID: 23337716
26. Diebold SS. Activation of dendritic cells by toll-like receptors and C-type lectins. Handbook of experimental pharmacology. 2009;(188):3-30. Epub 2008/11/26. https://doi.org/10.1007/978-3-540-71029-5-1 PMID: 19031019
27. Mustea A, Braicu EI, Koensgen D, Yuan S, Sun PM, Stamatian F, et al. Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. Cytokine. 2009; 45 (1):8-11. Epub 2008/12/17. https://doi.org/10.1016/j.cyto.2008.10.019 PMID: 19071030
28. Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y, et al. Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. Journal of experimental & clinical cancer research: CR. 2011; 30:62. Epub 2011/05/21.
29. Rabinovich A, Medina L, Piura B, Huleihel M. Expression of IL-10 in human normal and cancerous ovarian tissues and cells. European cytokine network. 2010; 21(2):122-8. Epub 2010/05/01. PMID: 20430716
30. Hawrylowicz CM, O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol. 2005; 5(4):271-83. Epub 2005/03/19. https://doi.org/10.1038/nri1589 PMID: 15775993
31. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis and rheumatism. 2000; 43(8):1790-800. Epub 2000/08/16. https://doi.org/10.1002/ 1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2 PMID: 10943869
32. Hart KM, Byrne KT, Molloy MJ, Usherwood EM, Berwin B. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Frontiers in immunology. 2011; 2:29. Epub 2011/01/01. https://doi.org/10.3389/fimmu.2011.00029 PMID: 22566819
33. Kalinski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001; 97(11):3466-9. Epub 2001/05/23. PMID: 11369638
34. Bekeredjian-Ding I, Schafer M, Hartmann E, Pries R, Parcina M, Schneider P, et al. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cellderived interferon-alpha. Immunology. 2009; 128(3):439-50. Epub 2010/01/14. https://doi.org/10.1111/ j.1365-2567.2009.03134.x PMID: 20067543
35. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 2005; 106(7):2375-81. Epub 2005/06/11. https://doi.org/10. 1182/blood-2005-03-0979 PMID: 15947091
36. von Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel MS, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood. 2006; 108(1):228-37. Epub 2006/03/09. https://doi.org/10.1182/blood-2005-08-3507 PMID: 16522817
37. Laudanski K, De A, Brouxhon S, Kyrkanides S, Miller-Graziano C. Abnormal PGE(2) regulation of monocyte TNF-alpha levels in trauma patients parallels development of a more macrophage-like phenotype. Shock. 2004; 22(3):204-12. Epub 2004/08/19. PMID: 15316388
38. Renz H, Gong JH, Schmidt A, Nain M, Gemsa D. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol. 1988; 141(7):2388-93. Epub 1988/10/01. PMID: 2844899
39. Hubbard LL, Ballinger MN, Thomas PE, Wilke CA, Standiford TJ, Kobayashi KS, et al. A role for IL-1 receptor-associated kinase-M in prostaglandin E2-induced immunosuppression post-bone marrow transplantation. J Immunol. 2010; 184(11):6299-308. Epub 2010/05/05. https://doi.org/10.4049/ jimmunol.0902828 PMID: 20439918
40. Lavoue V, Cabillic F, Toutirais O, Thedrez A, Dessarthe B, de La Pintiere CT, et al. Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vgamma9Vdelta2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy. International journal of cancer Journal international du cancer. 2012; 131(4):E449-62. Epub 2011/11/19. https://doi.org/10.1002/ijc.27353 PMID: 22095289
41. Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunological investigations. 2012; 41(6-7):635-57. Epub 2012/09/29. https://doi.org/10.3109/08820139.2012.695417 PMID: 23017139
42. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 2011; 187(3):1157-65. Epub 2011/06/29. https://doi.org/10.4049/jimmunol.1100889 PMID: 21709158
43. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K. Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Molecular cancer. 2006; 5:62. Epub 2006/ 11/17. https://doi.org/10.1186/1476-4598-5-62 PMID: 17107625
44. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16(5):1384-90. Epub 2010/02/25.
45. Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P. Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2013; 191:67-93. Epub 2012/08/16. https://doi.org/10.1007/ 978-3-642-30331-9-4 PMID: 22893200
46. Hahn T, Alvarez I, Kobie JJ, Ramanathapuram L, Dial S, Fulton A, et al. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. International journal of cancer Journal international du cancer. 2006; 118(9):2220-31. Epub 2005/12/07. https://doi.org/10.1002/ijc.21616 PMID: 16331615
47. Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V, et al. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(1):214-22. Epub 2006/01/07.